



**Press Release**  
Montrouge, France, April 27, 2018

## **DBV Technologies Reports March 31, 2018 Cash Position**

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) today announced its cash and cash equivalents as of March 31, 2018.

### **Cash and cash equivalents:**

Cash and cash equivalents as of March 31, 2018, were €234.5 million, compared to €137.9 million as of December 31, 2017.

### **Number of outstanding and fully diluted shares:**

As of March 31, 2018, DBV's number of outstanding shares was 29,718,352 ordinary shares and on a fully diluted basis<sup>i</sup>, the number of shares was 32,272,620.

### **About DBV Technologies**

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: [www.dbv-technologies.com](http://www.dbv-technologies.com)



### **DBV Investor Relations Contact**

**Sara Blum Sherman**

Senior Director, Investor Relations & Strategy

+1 212-271-0740

[sara.sherman@dbv-technologies.com](mailto:sara.sherman@dbv-technologies.com)

### **DBV Media Contact**

**Raul Damas**

Partner, Brunswick Group

+1-212-333-3810

[DBV@brunswickgroup.com](mailto:DBV@brunswickgroup.com)

---

<sup>i</sup> fully diluted share capital represents all issued and outstanding shares, as well as all potential shares which may be issued upon exercise of outstanding employee warrants, employee performance shares and share options and nonemployee warrants, as approved by DBV Technologies shareholders and granted by the board of directors.